000 01336nam a2200337 a 4500
005 20250913110146.0
008 981208s1985 xxua 00 eng b
010 _a85-004452
020 _a0444904077
039 9 _a200606021158
_bjamil
_c200606021157
_djamil
_y08-18-1999
_zload
060 _aWR220
_b.B131 1984
090 _aWR220.B131 1984 9HUKM
245 0 0 _aBactroban (mupirocin BRL 4910) :
_bproceedings of an international symposium, Nassau, May 21-22, 1984 /
_ceditors, R. L. Dobson ...[et al.]
260 _aNew York :
_bElsevier Science,
_c1985
300 _a269 p. :
_bill. ;
_c25 cm.
440 0 _aCurrent clinical practice series,
_v16
650 0 _aSkin
_xInfections
_xChemotherapy
_xEvaluation
_vCongresses
650 0 _aMupirocin
_xTesting
_vCongresses
650 0 _aPyoderma
_xChemotherapy
_xEvaluation
_vCongresses
650 0 _aAntibiotics
_xTherapeutic use
_vCongresses
650 0 _aSkin Diseases, Infectious
_xdrug therapy
_vCongresses
650 0 _aFatty acids
_xPharmacodynamics
_vCongresses
650 0 _aFatty acids
_xTherapeutic use
_vCongresses
700 1 _aDobson, Richard L
907 _a.b1017297x
_b2019-11-12
_c2019-11-12
942 _c01
_n0
_kWR220.B131 1984 9HUKM
914 _avtls000018142
991 _aFakulti Perubatan
998 _ah
_b1999-05-08
_cm
_da
_feng
_gxxu
_y0
_z.b1017297x
999 _c19319
_d19319